Novo Nordisk and Karolinska Institutet collaborate on diabetes postdoctoral research program

10 February 2015

Danish insulin giant Novo Nordisk (NOV: N) is to join forces with Swedish researchers Karolinska Institutet for diabetes research.

The program will be fully funded by Novo Nordisk, and is a postdoctoral fellowship with 12 researchers being offered three-year grants to research diabetes and metabolism. Research will be carried out at Karolinska Institutet in Stockholm.

Anders Hamsten, vice chancellor of Karolinska Institutet, said: "Novo Nordisk is the world leader in diabetes, and this initiative is of strategic importance both to them and to us. The agreement creates a unique opportunity for recruiting young diabetes researchers to Karolinska Institutet."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK